Surface Transforms management deliver positive operational update 16.09.2019 Watch Now

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price: 0.34
Bid: 0.33
Ask: 0.35
Change: 0.005 (1.49%)
Spread: 0.02 (6.06%)
Open: 0.335
High: 0.34
Low: 0.335
Yest. Close: 0.335
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Notice of Interim Results

Thu, 9th Feb 2017 07:00

RNS Number : 3549W
Sareum Holdings PLC
09 February 2017

(AIM: SAR)

9 February 2017

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Notice of Interim Results

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, announces that it expects to release its interim results for the six months to 31 December 2016 on Monday 20 February 2017.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)

Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Sareum Media enquiries)

Ariane Comstive Ariane.comstive@communications-portfolio.co.uk

07785 922 354

Notes for Editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology (previously ProNAi Therapeutics) in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFSLFSITIID

Login to your account

Don't have an account? Click here to register.